Agile Therapeutics Future Growth
Future criteria checks 5/6
Agile Therapeutics is forecast to grow earnings and revenue by 67.8% and 39.5% per annum respectively while EPS is expected to grow by 70.5% per annum.
Key information
67.8%
Earnings growth rate
70.5%
EPS growth rate
Pharmaceuticals earnings growth | 20.4% |
Revenue growth rate | 39.5% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 26 Jun 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 61 | 11 | N/A | N/A | 2 |
12/31/2024 | 36 | -9 | N/A | N/A | 2 |
12/31/2023 | 22 | -19 | N/A | N/A | 2 |
3/31/2023 | 13 | -20 | -23 | -23 | N/A |
12/31/2022 | 11 | -25 | -36 | -36 | N/A |
9/30/2022 | 8 | -62 | -51 | -51 | N/A |
6/30/2022 | 7 | -59 | -53 | -53 | N/A |
3/31/2022 | 6 | -64 | -66 | -65 | N/A |
12/31/2021 | 4 | -71 | -65 | -65 | N/A |
9/30/2021 | 3 | -69 | -66 | -66 | N/A |
6/30/2021 | 2 | -68 | -63 | -63 | N/A |
3/31/2021 | 1 | -61 | -54 | -54 | N/A |
12/31/2020 | 1 | -52 | -48 | -47 | N/A |
9/30/2020 | N/A | -40 | -34 | -33 | N/A |
6/30/2020 | N/A | -29 | -23 | -23 | N/A |
3/31/2020 | N/A | -22 | -19 | -19 | N/A |
12/31/2019 | N/A | -19 | -16 | -16 | N/A |
9/30/2019 | N/A | -16 | -16 | -16 | N/A |
6/30/2019 | N/A | -16 | -14 | -14 | N/A |
3/31/2019 | N/A | -18 | -16 | -16 | N/A |
12/31/2018 | N/A | -20 | -17 | -17 | N/A |
9/30/2018 | N/A | -22 | -20 | -20 | N/A |
6/30/2018 | N/A | -26 | -24 | -23 | N/A |
3/31/2018 | N/A | -28 | -26 | -24 | N/A |
12/31/2017 | N/A | -28 | -26 | -25 | N/A |
9/30/2017 | N/A | -27 | -22 | -22 | N/A |
6/30/2017 | N/A | -28 | -23 | -22 | N/A |
3/31/2017 | N/A | -29 | -23 | -23 | N/A |
12/31/2016 | N/A | -29 | N/A | -23 | N/A |
9/30/2016 | N/A | -27 | N/A | -25 | N/A |
6/30/2016 | N/A | -29 | N/A | -25 | N/A |
3/31/2016 | N/A | -29 | N/A | -27 | N/A |
12/31/2015 | N/A | -30 | N/A | -25 | N/A |
9/30/2015 | N/A | -33 | N/A | -26 | N/A |
6/30/2015 | N/A | -30 | N/A | -26 | N/A |
3/31/2015 | N/A | -25 | N/A | -21 | N/A |
12/31/2014 | N/A | -16 | N/A | -15 | N/A |
9/30/2014 | N/A | -12 | N/A | -11 | N/A |
6/30/2014 | N/A | -9 | N/A | -7 | N/A |
3/31/2014 | N/A | -10 | N/A | -8 | N/A |
12/31/2013 | N/A | -14 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0AL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).
Earnings vs Market: 0AL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 0AL is expected to become profitable in the next 3 years.
Revenue vs Market: 0AL's revenue (39.5% per year) is forecast to grow faster than the German market (4.6% per year).
High Growth Revenue: 0AL's revenue (39.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0AL's Return on Equity is forecast to be high in 3 years time